News
The case involved a clinical trial of Akero's only product, a drug candidate aimed at treating a liver disease. It's the ...
5d
TipRanks on MSNAkero Therapeutics’ efruxifermin shows efficacy in Phase 2b MASH, fibrosis trial
Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of ...
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASHSOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE ...
EFX is now being further evaluated in three ongoing Phase 3 trials targeting all stages of MASH. EFX, Akero's lead candidate, is an FGF21 analog designed for once-weekly dosing.
Equifax faces growth headwinds, premium valuation, and flat price action despite AI and cloud investments, with limited ...
15d
Zacks Investment Research on MSNCRAI vs. EFX: Which Stock Is the Better Value Option?
Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with ...
Equifax Inc. Annual stock financials by MarketWatch. View the latest EFX financial statements, income statements and financial ratios.
EFX continues to strive to bring you prop replicas of the highest level of authenticity and accuracy possible. This edition is no different, it utilizes parts cast from the same master patterns ...
Guitarist, composer, and arranger Chieli Minucci is longtime leader of the Grammy-nominated jazz-fusion group CHIELI MINUCCI & SPECIAL EFX, a major force on the jazz and world music scene for well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results